Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2002-07-17
2008-08-12
Helms, Larry (Department: 1642)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C514S04400A, C424S199100, C424S093200, C424S093600
Reexamination Certificate
active
07410644
ABSTRACT:
Recombinant pox viruses capable of expressing cell-encoded, tumor-associated antigens are disclosed. The recombinant viruses are useful for evoking an immune response against the antigen.
REFERENCES:
patent: 5174993 (1992-12-01), Paoletti
patent: 5266313 (1993-11-01), Esposito et al.
patent: 5382425 (1995-01-01), Cochran et al.
patent: WO 92/19266 (1992-11-01), None
patent: WO 94/16176 (1994-08-01), None
patent: WO 96/10419 (1996-04-01), None
patent: WO 96/10419 (1996-04-01), None
patent: WO 96/11279 (1996-04-01), None
patent: WO 96/11279 (1996-04-01), None
patent: WO 96/11279 (1996-04-01), None
patent: WO 96/26271 (1996-08-01), None
patent: WO 97/03203 (1997-01-01), None
Kundig et al (Vaccine, 1993, 11:1154-1158).
ICTVbB Index of Viruses, pp.1-10.
“The Assessment of Future Scientific Needs for Live Variola Virus” p. 1-3; Chapter II, p. 1-6.
“Third World Network Biosafety information service”, May 19, 2005, p. 1-3.
Von Mehren et al (Clinical Cancer Research, 2000, 6:2219-2228).
Hodge et al (Vaccine, 1997, 15:759-768).
Hodge et al II (Cancer Research, 1995, 15:3598-603).
Ontario Ministry of Agriculture Food and Rural Affairs “fact sheet” p. 1-12.
Marshall et al (J Clinical Oncology, 2000, 18:3964-3973).
Cooney et al (The Lancet, 1991, 337:567-572).
Kass-Eisler et al (Gene Therapy, Feb. 1996, 3:154-162).
Hellstrom, K.E., et al., Adv. Cancer Res. 12:167-223 (1969).
Greenberg, P.D., Advances in Immunology, 49: 281-355 (1991).
Boon, T., et al., Annu. Rev. Immunol. 12:337-365 (1994).
Brithcard, V., et al., J. Exp. Med. 178:489-495 (1993).
Cox, A.L., et al., Science 264:716-719 (1994).
Houghton, A.N., J. Exp. Med. 180:1-4 (1994).
Pardoll, D.M., Nature 369:357-358 (1994).
Kawakami, Y., et al., Proc. Natl. Acad. Sci. U.S.A. 91:3515-3519 (1994).
Kawakami, Y., et al., Proc. Natl. Acad. Sci. U.S.A. 91:6458-6462 (1994).
Muraro, R., et al., Cancer Res. 4S:5769-5780 (1985).
Kantor, J., et al., J. Natl. Cancer Inst. 84:1084-1091 (1992).
Robbins, P.F., et al., Cancer Res. 51:3657-3662 (1991).
Kantor, J., et al., Cancer Res. 52:6917-6925 (1992).
Wang, M.C., et al., Meth. Cancer Res. 19:179-197 (1982).
Carter, H.B., et al., Cancer Research 52:3323-3328 (1992).
Austin, F.C., et al., Adv. Cancer Res. 50:301-345 (1979).
Taylor, J., et al., Vaccine 6:497-503 (1988).
Technological Advances in Vaccine Development (Alan R. Liss, Inc.) pp. 321-334.
Wild, T.F., et al., Vaccine 8:441-442 (1990).
Balloul, et al., Cell Mol. Biol. 40 (Suppl. I.):49-59 (1994).
Irvine, et al., Vaccine Research, 2(2):79-94 (1993).
Hodge, et al., Int. J. Cancer 63:231-237 (1995).
Taang et al., J. Nat'l Cancer Inst., 87(13):982-990 (1995).
Bu et al., J. of Immunotherapy 14:127-135 (1993).
Acres et al., Int. J. Cancer 63:31-237 (1995).
Tartaglia et al.,J Virol67 (1993) 2370-2375.
Paoletti. 1996.,PNAS93:11349-11353.
Romero et al.,Vaccine11(1993) 737-742.
Therasse P. Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumor assessment. Eur J Cancer 2006;42:1031-9.
Tuma RS. Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints, J Natl Cancer Inst. 2006;98(18):1272-4.
Gore ME, Escudier B. Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma. Oncology (Williston Park). 2006;20(6 Suppl 5):19-24. Review.
Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, et al. A clinical development paradigm for cancer vaccines and related biologics, J Immunother 2007;30:1-15. Review.
Escudier B, Eisen T, Sadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
Hodge JW, Scholm J, Abrams SI, Vaccines and immunostimulants. In: Kufe DW, Bast Jr. RC, Hait WN, Hong WK, Pollack RE, Weichselbaum RR, et al., eds. Holland-Frei Cancer Medicine 7, 7th ed. Hamilton, Ontario: BC Decker; 2006:786-801.
Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen independent prostate cancer. Clin Cancer Res 2006;12:1260-9. http://clincancerres.aacrjournals.org/cgi/content/full/12/4/1260.
Arlen PM, Gulley JL, Todd N, Lieberman R, Steinberg SM, Morin S, Bastian A, Marte J, Tsand K-Y, Beetham P, Grosenbach DW, Scholm J, Dahunt W. Antiandrogen, vaccine and combination therapy in nonmetastatic hormone refractory prostate cancer patients. J. Urol. 174:539-546,2005. http:/linkinghub.elsevier.com/retrieve/pii/S0022534701683034.
Madan RA, Gulley JL, Dahut WL, Steinberg S, Liewehr D, Scholm J, et al. An analysis of the 5-year overall survival (OS) in non-metastatic androgen independent prostate cancer (AIPC) patients (pts) treated with nilutamide (N), vaccine (V), and combination therapy. 2007 Prostate Cancer Symposium. Abstract (in press).
Akagi, J, Hodge J, McLaughlin JP, Gritz L, Mazzara G, Kufe D, Scholm J, Kantor JA. et al. Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7. Journal of Immunotherapy 20(1);38-47, 1997.
Gritz Linda R.
Mazzara Gail P.
Panicali Dennis L.
Schlom Jeffrey
Goddard Laura B
Helms Larry
Leydig , Voit & Mayer, Ltd.
The United States of America as represented by the Department of
LandOfFree
Recombinant pox virus for immunization against... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant pox virus for immunization against..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant pox virus for immunization against... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4019306